Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Hacker Teen Uses 'Swatting' to Harass Online Gamers
09:14 - Bloomberg's Emily Chang reports on the teenage hacker who admitted to "swatting" online gamers. She speaks on "Bloomberg West." (Source: Bloomberg)
  • How Close Are We to an Uber IPO?
  • The Top Three Things to Watch for at Google I/O
  • U.S. Economy Set Up for Sept. or Oct. Rate Hike: Kleintop